

# Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA

Na Hee Lee, MD<sup>1</sup>, Sung Yoon Cho, MD<sup>1</sup>, Se Hyun Maeng, MD<sup>1</sup>, Tae Yeon Jeon, MD<sup>2</sup>, Young Bae Sohn, MD, PhD<sup>3</sup>, Su Jin Kim, MD, PhD<sup>4</sup>, Hyung-Doo Park, MD, PhD<sup>5</sup>, Dong Kyu Jin, MD, PhD<sup>1</sup>

Departments of <sup>1</sup>Pediatrics, <sup>2</sup>Radiology & Center for Imaging Science, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, <sup>3</sup>Department of Medical Genetics, Ajou University School of Medicine, Suwon, <sup>4</sup>Center of Pediatric Oncology, National Cancer Center, Goyang, <sup>5</sup>Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Korea

To the Editor:

We found an error in our published article:

Lee NH, Cho SY, Maeng SH, Jeon TY, Sohn YB, Kim SJ, Park HD, Jin DK. Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA. Korean J Pediatr 2012;55:430-11. <http://dx.doi.org/10.3345/kjp.2012.55.11.430>

Page 435,

Nomenclature should be modified as follows:

One mutation of c.1568A>G (p.X523W) in patient 6 was a novel homozygous mutation. But we didn't have approval of family study in this patient.

Table 4 should be modified as follows:

**Table 4.** Biochemical and Genetic Characteristics of Korean Patients with Mucopolysaccharidosis IVA

	Phenotype	GAG level* (CPC unit/g creatinine)	Leukocyte GALNS Activity <sup>†</sup> (pmol/min/mg protein)	GALNS mutation
P1	Intermediate	195.4	0.3	c.218A>G (p.Y73C), c.725C>G (p.S242C)
P2	Severe	585.2	3.1 <sup>‡</sup>	c.752G>A (p.R251Q), c.451C>A (p.P151T)
P3	Severe	133.3	0.2	c.1243-1G>A (IVS11 1G>A), c.451C>A (p.P151T)
P4 <sup>  </sup>	Severe	192.7	<0.1	c.451C>A (p.P151T), c.1000C>T (p.Q334X)
P5 <sup>  </sup>	Severe	472.5	0.3	c.451C>A (p.P151T), c.1000C>T (p.Q334X)
P6	Severe	230.4	0.2	c.1000C>T (p.Q334X), c.1156C>T (p.R386C)
P7	Severe	420	0.78	c.1568A>G (p.X523W) <sup>§</sup> , c.1568A>G (p.X523W) <sup>§</sup>
P8 <sup>¶</sup>	Severe	NA	8.27	c.451C>A (p.P151T), c.415G>A (p.G139S)
P9 <sup>¶</sup>	Severe	NA	6.4	c.451C>A (p.P151T), c.415G>A (p.G139S)
P10	Severe	167.5	1.43	c.1000C>T (p.Q334X), c.853_855delTTC (p.F285 del)

P, patient; GAG, glycosaminoglycan; CPC, cerylpyridinium chloride; NA, not available.

\*Normal ranges of GAG level are <375 CPC unit/g creatinine (age, <1 year), <175 CPC unit/g creatinine (age, 1 to 9 years) and <85 CPC unit/g creatinine (age, >9 years) in random urine. <sup>†</sup>Normal ranges of GALNS activity are 39 to 166 pmol/min/mg protein in leukocytes and 18 to 72 pmol/min/mg protein in skin fibroblasts. <sup>‡</sup>Skin fibroblast GALNS activity. <sup>§</sup>Novel mutation. <sup>||</sup>Family 1. <sup>¶</sup>Family 2.